No biomarker No biomarker	Oral Cancer Oral Cancer	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Oral Cancer Oral Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	methotrexate Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cisplatin + docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cetuximab Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	afatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cisplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cisplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
No biomarker No biomarker	Oral Cancer Oral Cancer	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
GDF15 overexpression GDF15 overexpression	Oral Cancer Oral Cancer	TPF Sensitive: C3 – Early Trials
POU5F1 overexpression + NANOG overexpression POU5F1 overexpression + NANOG overexpression	Oral Cancer Oral Cancer	cisplatin Resistant: C3 – Early Trials
miR-1290-L miR-1290-L	Oral Cancer Oral Cancer	5-fluorouracil Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Oral Cancer Oral Cancer	cetuximab Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	nivolumab + MGCD516 Sensitive: C3 – Early Trials
CHEK2 mutation CHEK2 mutation	Tongue Carcinoma Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies
FGFR2 P253R FGFR2 P253R	Tongue Carcinoma Tongue Carcinoma	cetuximab Sensitive: C4 – Case Studies
FGFR2 P253R FGFR2 P253R	Tongue Carcinoma Tongue Carcinoma	pazopanib Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	nivolumab + nimotuzumab Sensitive: C4 – Case Studies
CMTM6 overexpression CMTM6 overexpression	Oral Cancer Oral Cancer	cisplatin Resistant: D – Preclinical
EGF expression EGF expression	Tongue Carcinoma Tongue Carcinoma	cetuximab Resistant: D – Preclinical
PIK3CA Q546R PIK3CA Q546R	Oral Cancer Oral Cancer	palbociclib Resistant: D – Preclinical
PIK3CA H1047L PIK3CA H1047L	Oral Cancer Oral Cancer	palbociclib Resistant: D – Preclinical
miR-155 overexpression miR-155 overexpression	Oral Cancer Oral Cancer	cisplatin Resistant: D – Preclinical
FOXO3 underexpression FOXO3 underexpression	Oral Cancer Oral Cancer	cisplatin Resistant: D – Preclinical

Oral Cancer

Associations(34)

Associations
(34)